Bovine immunodeficiency virus (BIV) is a nonacute pathogenic retrovirus and a member of the lentivirus genus. BIV shares biologic, genetic, and pathologic characteristics with lentiviruses that cause chronic inflammatory diseases and immunodeficiencies (5, 16, 43 ; reviewed in references 13 to 15 and 17) . Similarities between BIV and the human and simian immunodeficiency viruses (HIV and SIV, respectively) extend to ultrastructure, genome organization, catalytic functions of pol gene products, and immunological cross-reactivity of the Gag proteins (1, 4, 11, 16, 26, 35) . Sequencing of functional molecular clones of BIV has shown that its genome includes the obligate gag, pol, and env retroviral structural genes as well as six putative nonstructural accessory genes (tat, rev, vif, vpw, vpy, and tmx) (4, 11, 13, 29, (32) (33) (34) .
The BIV gag gene encodes a 53-kDa precursor protein, Pr53rag (1, 35) , that participates in the formation of immature virions and assembles into virus-like particles when produced in the baculovirus-insect cell expression system (35) . The processing of lentivirus Gag precursors by an aspartyl-type viral protease (PR) leads to the formation of five to six major proteolytic cleavage products (7, 19, 20, 23) . Immunologic analyses of proteins from BIV virions with monospecific anti-BIV and -HIV type 1 (HIV-1) sera have resolved three major Gag cleavage products, the matrix, capsid, and nucleocapsid proteins (MA [p16MAI, CA [p26CA] , and NC [pl3NCI, respectively) (1, 35) . A definition of the N and C termini of the three known Gag proteins and the exact number of Gag proteins contained within the BIV Gag precursor, however, have not been determined in previous studies (1, 35) .
In the present report, the mature Gag proteins from BIV virions obtained from molecularly cloned BIV R29-127 were purified by reversed-phase, high-pressure liquid chromatography (rp-HPLC) and identified by immunoblotting with monospecific sera. N-terminal sequencing, amino acid composition, and mass spectrometry (MS) were used to calculate the molecular weight and to determine N and C termini of each isolated BIV Gag protein. These data precisely identified the proteolytic cleavage sites in and thus the subunit organization of Pr53raS. In addition to the requisite MA, CA, and NC proteins, three small intragenic Gag cleavage fragments were identified, as was the lack of a fatty acid modification at the N terminus of the MA. The molecular masses of the BIV MA, CA, and NC proteins were determined by MS and are in agreement with those deduced from amino acid analyses. A comparison of these data with those derived from the study of HIV-1 and other retroviruses is discussed.
Isolation, amino acid analyses, and MS of BIV Gag proteins. Virus was harvested from Cf2Th cultures transfected with the BIV R29-127 molecular clone, isolated by continuous-flow sucrose density gradient centrifugation, and further concentrated by ultracentrifugation (2, 42) . Virions were disrupted and reduced by the addition of solid guanidine hydrochloride and 2-mercaptoethanol in the presence of 3.7 ,uM zinc acetate to protect the putative zinc-binding NC protein. The virus preparation was sonicated and equilibrated to pH 2 with trifluoroacetic acid. Materials were loaded onto piBondapack C18 rp-HPLC supports (25 by 100 mm) in 0.05% (vol/vol) trifluoroacetic acid at pH 2 and eluted with a gradient of increasing acetonitrile concentrations in 0.05% trifluoroacetic acid, as previously described (20) . Eluted proteins and peptides were detected by determining the UV A206, A280, and A294; collected; and lyophilized. The spectra at 206 nm are shown in Fig. 1A .
Peak fractions of the rp-HPLC separation were analyzed by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and visualized by Coomassie staining (Fig. 1B ) and immunoblot analysis (Fig. 1C) . The predominant species in fractions 173 through 219 were identified as pl6MA and p26CA (data not shown) but were not sufficiently resolved for subsequent analyses. Therefore, fractions 173 to 186, 187 to 199, and 201 to 219 were combined into pools I, II, and III, respectively, for additional rp-HPLC purifications (Fig. 1A,  insets) . Rechromatography of pooled fractions I, II, and III was performed over 3 h using 38 to 52% acetonitrile gradients at flow rates of 5 ml/min (Fig. 1A, insets previously described (20) , to define the N-and C-terminal boundaries of isolated Gag proteins. By comparing results of these analyses with the translation predicted from the DNA sequence (11) , the probable C-terminal residues of each protein were determined. The amino acid compositions and N-terminal sequence analyses are summarized in Table 1 (Fig. 1A) , was identi- fied in SDS-PAGE and immunoblots using a peptide antiserum specific to the C terminus of CA (Fig. 1B and C, lanes  6 ). Edman degradation of ploCA identified the Ala-274 of Pr535ar as its N terminus (Fig. 2) . Because of the detection of at least two phenylalanines by compositional analysis (Table  1) , plOcA most likely shares its C terminus with p26CA (Fig. 2) .
Thus, plOCA contains the 94 C-terminal residues of p26CA and has a calculated mass of 10,381.9 Da. Although not immunologically identified, a second minor CA cleavage product with an apparent molecular mass of 11 kDa also was found in fraction 140. Sequence analysis identified its N-terminal residue as Gly-179 of Pr53rag (Fig. 2) . Its mobility in SDS-PAGE suggests that its C terminus was generated by proteolytic cleavage between Ala-273 and Ala-274. This CA peptide is predicted to have a mass of 10,804.3 Da and thus represents an internal CA fragment of 95 residues. Both the 10-and 11-kDa CA fragments were present in a molar ratio of approximately 2% with respect to the intact p26CA. A putative peptide containing the amino-terminal 30 residues with a predicted mass of 3,445.8 Da was not identified in the rp-HPLC separation. The functions, if any, of the secondary CA cleavage products are not known.
(iii) NC proteins. A 13-kDa BIV protein previously was identified with HIV and BIV NC-specific antisera in immunoblots and radioimmunoprecipitations (1) . The BIV NC eluted in fraction 25 of the HPLC gradient (Fig. 1A) and migrated as a 13-kDa protein in gel electrophoresis (Fig. 1B and C, lanes  3 ).
All 66 residues of the NC protein were confirmed by amino acid sequence analysis (Fig. 2) . The presence of three alanine, one phenylalanine, three tyrosine, and three histidine residues characterizes the termini of the NC protein ( Table 1 ). The N and C termini were Ala-393 and Phe-458 of Pr53Yar, respectively, and the BIV NC protein, p13NC, has a calculated mass of 7,287.1 Da.
ESI-MS was of particular value in resolving the discrepancy between the molecular weights of the NC protein predicted by gel mobility and determined by amino acid composition. The ESI-MS of HPLC fractions 25 to 27 (Fig. 1A) characterizes an NC species of 7,283 Da ( Fig. 3C and Table 2 ), which is in good agreement with the calculated mass of 7,287.1 Da. Minor NC proteins with masses of 7,475, 7,538, and 7,122 Da also were detected (Fig. 3C) . The 7,283-, 7,475-, and 7,538-Da forms of NC were present in molar fractions of approximately 43, 18 , and 37% of the total NC found. No evidence for dimeric forms of NC protein was found.
(iv) Small Pr53ya9 cleavage products. Three small Gagrelated peptides also were isolated during rp-HPLC separation of the viral proteins and were sequenced in their entirety. Fraction 21 (Fig. 1A) contained a peptide, designated p2L, which had a relative migration of 3 kDa in SDS-PAGE and was reactive to an antiserum directed to a region between the MA and CA proteins (Fig. 1B and C, lanes 2 ). Fraction 21 (Fig. 1A) also contained p13NC that appeared to coelute with p2L (Fig.  1B, lane 2) . N-terminal sequence analysis indicated that the N and C termini of p2L in fraction 21 were Pro-127 and Leu-148 (Fig. 1A) . (Table 2) . Two minor cleavage products of p2L that contained 7 and 8% of the total p2L were found in peaks a and b (Fig. 1A) , respectively. The N-terminal proline was absent from the p2L in peak a, and the 10 N-terminal residues were missing from the p2L in peak b. A second small peptide, p2, identified by amino acid analysis 12+ as the C-terminal protein of the Gag precursor, eluted in fraction 61 (Fig. 1A) (Fig. 1A) . Peaks c and d were missing four and five N-terminal residues (Fig. 2) and contained 46 and 31% of the total p2 material, respectively. A third peptide, p3, eluted in fraction 85 (Fig. lA) ; it appeared as a diffuse band by SDS-PAGE but could not be visualized in immunoblot analysis ( Fig. lB and C, lanes 5 ). Amino acid compositional and sequence analyses confirmed the N and C termini of p13 (Table 1) as Leu-368 and Tyr-392 of Pr53yag, 'respectively ( Fig. 2) . p3 has a calculated molecular mass of 2,664.2 Da. Peaks e and f, isolated from fractions 71 and 80 of the rp-HPLC separation, contained 20 and 14% of the total p13 material (Fig. 1A) and were missing one and six N-terminal residues, respectively (Fig. 2) In conclusion, several studies have determined the amino acid sequences of lentivirus Gag proteins purified from mature virions and deduced the subunit organization of the Gag precursors (7, 19, 20, 23) . In addition to BIV MA, CA, and NC functional proteins, three small Gag proteins (p2L, p3, and p2) were characterized in the present study, which indicated that the processing of the BIV Gag precursor is more complex than was revealed from the previous detailed immunological studies (1, 35) . Comparison of the empirically derived amino acid sequences with those predicted from translation of the BIV DNA sequence (11) demonstrates that the order of the six major proteins in the BIV Gag precursor is NH2-MA-p2L-CAp3-NC-p2-COOH.
Most retroviral Gag precursor N termini are posttranslationally modified by fatty acids (e.g., myristic acid), which is believed to play a role in localizing the Gag precursor to the plasma membrane during virus assembly (7, 19-21, 31, 36, 37, 39, 40 (37) . Therefore, while myristylation may be important in some systems, an alternative mechanism must exist for the localization of the BIV Gag precursor in the plasma membrane and assembly of the virus particle.
A C-terminal protein is also present in BIV; however, in contrast to the MA, CA, and NC proteins, the C-terminal proteins of lentiviruses from different species are quite variable in size and range from 2 to 9 kDa. Several studies suggest that the HIV-1 C-terminal protein (p6) has a role in virus assembly (12, 28) ; however, deletion of C-terminal residues still results in particle formation in the baculovirus-insect cell expression system (41) . Thus, the role of p6 in the HIV-1 Gag precursor remains controversial. Alignment of the C-terminal domains of several lentiviruses demonstrates that BIV p2 contains a conserved PS/TAPP motif (data not shown). The presence of this conserved domain suggests a common, albeit unknown, function. Although the amino acid sequences of ovine and caprine Gag proteins have not been determined, the proximity of the PS/TAPP motif to the C termini of their Gag precursors suggests that their putative C-terminal Gag proteins are similar in size to the BIV p2. The only lentivirus that lacks the PS/TAPP domain is equine infectious anemia virus, which is also the only lentivirus that lacks a vif gene (27, 32) . Vif has been implicated in the increased infectivity of the lentivirus virion (3, 6) . Although the mechanism of this phenomenon is unknown, it could be conjectured that Vif interacts with other viral proteins, such as the C terminus of the Gag precursor, during the budding process.
BIV is unique among the lentiviruses in having an intragenic peptide (p2L) between the MA and CA proteins. Such a peptide has been described for other retrovirus genera (22, 25) .
DNA sequence data indicate that new field isolates of BIV contain p2L and, despite p2L sequence heterogeneity, residues in the cleavage sites are well conserved (10) . In lentiviruses, a small peptide resides between the CA and NC domains; 5-, 17-, 14-, and 9-residue peptides are removed during processing of the CA and NC proteins of equine infectious anemia virus (23) , SIV (19) , HIV-1 (20) , and feline immunodeficiency virus (7), respectively. This peptide (p3) in BIV is slightly larger, 25 residues. A small peptide is also found between the NC and C-terminal proteins in HIV-1 and SIV (19, 20) ; in contrast, BIV, equine infectious anemia virus, and feline immunodeficiency virus lack this peptide (7, 23) . Whether the small intragenic peptides are simply spacer peptides used in processing the Gag precursor by the viral PR or are necessary for interaction with other Gag precursor domains during virus assembly is unknown.
The BIV NC protein has been referred to as p13NC on the basis of its mobility in denaturing gels (1, 35) . The original predicted molecular mass (13 kDa) based on the amino acid translation for the BIV NC protein did not take into account the cleavage of the CA-NC intragenic p3 or the C-terminal p2 (11) . The MS and the amino acid sequence data generated in the present study (Table 2 ) are in good agreement and indicate that the mass of the NC protein is 7.3 kDa. Its slow electrophoretic mobility in denaturing gel electrophoresis is probably a result of a high pl of 10.47 .
When the PR cleavage sites for the BIV Gag precursor are compared with those of HIV-1 (20) , only the BIV MA-p2L (Tyr-Pro) and HIV-1 MA-CA (Tyr-Pro) sites appear to be conserved. Interestingly, preliminary experiments using recombinant HIV-1 and BIV PRs indicate that recombinant BIV and HIV-1 Gag precursors can be cleaved by either viral PR to yield some of the expected mature products found in the virion (41) . When the BIV PR sequence was fitted to the threedimensional structure of the HIV-1 PR (44), the active sites of the two PR dimers were superimposable with the exception of two residues, despite limited sequence similarity (8) . Although the mechanism by which viral PRs recognize and cleave Gag precursor is not completely understood, the cleavage sites are believed to be determined largely by the primary amino acid sequence and conformation of precursor polyproteins in the immature particle (19) . Further investigation into the processing of the recombinant BIV Gag precursor by heterologous viral PRs should identify the cleavage sites used in vitro and provide information on the mechanism of viral PR specificity. Moreover, knowledge of viral PR cleavage sites in the Gag precursor will facilitate the molecular cloning and expression of individual BIV Gag proteins for further study.
